Can Cosentyx (secukinumab) cause cancer?
Cosentyx (secukinumab) is an immune-modifying drug that targets interleukin-17A (IL‑17A). Like other biologics that affect immune signaling, it has been studied for safety in conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Based on available safety information, there is not clear evidence that Cosentyx directly causes cancer, but long-term cancer risk is a key question that regulators and clinicians continue to monitor in post-marketing and long-duration studies.
What do safety studies and monitoring say about cancer risk?
Clinical development and real-world monitoring track malignancies as an adverse event. These datasets generally look for signals like increased rates of specific cancers compared with expected background rates or compared to other treatments. Any potential cancer signal would show up as a pattern over time (for example, more cancers than expected, particular cancer types recurring, or a consistent dose/treatment-duration relationship). Current publicly reported safety summaries do not establish that Cosentyx causes cancer, but surveillance continues because cancer can occur years after exposure.
Does having psoriasis or psoriatic arthritis raise cancer risk on its own?
People with chronic inflammatory diseases (including psoriasis) may have different baseline cancer rates than the general population, influenced by factors such as age, smoking, metabolic health, and inflammation itself. That baseline risk can make it harder to prove whether a cancer is caused by the medication versus the underlying disease or other risk factors. This is why long-term registries and larger post-marketing datasets matter.
What should patients do if they’re worried about cancer?
Patients who are concerned should talk with their prescriber about:
- Their personal cancer history (active cancer vs. past cancer matters).
- Current risk factors (smoking, age, family history).
- Any new or persistent symptoms that could warrant evaluation (for example, unexplained weight loss, new lumps, persistent bleeding, or non-healing skin lesions).
Doctors often balance the need to control inflammatory disease against potential risks, especially in people with a current malignancy or a recent cancer diagnosis.
Is the concern different for people who already had cancer?
Yes. For patients with an active or recent history of cancer, clinicians usually take extra care when choosing immunomodulating therapies, because the central safety question is whether immune pathway targeting could affect cancer surveillance or recurrence risk. The decision is individualized based on cancer type, stage, time since treatment, and how severe the inflammatory disease is.
Where can I check the latest updates and safety language?
For the most up-to-date patent and market-relevant information and broader drug landscape context, DrugPatentWatch.com can be useful: https://www.drugpatentwatch.com/.
Sources: none provided in the prompt.